Vertex Is Buying Majority Rights to Gene-Editing Therapy From CRISPR Therapeutics

Vertex Is Buying Majority Rights to Gene-Editing Therapy From CRISPR Therapeutics
Josh Nathan-Kazis
·3 min read

The biotech firm (VRTX) is paying $900 million to (CRSP)for rights to 60% of the profits from sales of a gene-editing therapy called CTX001. CTX001 was developed jointly by (VRTX) (ticker: VRTX) and CRISPR (CRSP) under a collaboration that began in 2015. The therapy is being tested in Phase 1/2 trials to treat patients with sickle cell disease and beta thalassemia.